"Moderna adds new cohort to Phase III vaccine trial after interim data miss" was originally created and published by Clinical ...

The Food and Drug Administration has approved a new flu vaccine made with the same mRNA technology that was used for the COVID-19 shots.

Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...

Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.  | Despite a major curveball thrown by the ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but US government regulators want to see data on whether the new vaccine protects people from getting sick.

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Moderna (MRNA) valuation in focus: weak Q2, cash outlook, FDA win for mFLUSIVA, pipeline risks and sales hurdles.

FILE - A vial of Moderna COVID-19 vaccine rests on a table at an inoculation station in Jackson, Miss., on July 19, 2022. (AP Photo/Rogelio V. Solis, File) (Rogelio V ...